Nava Therapeutics Unveils $89 Million Funding to Revolutionize CAR-T Therapy

Nava Therapeutics has emerged from stealth mode, announcing an $89 million funding round and a novel lipid nanoparticle platform aimed at targeting immune cells and kidneys. The funding will advance preclinical programs, including its promising in vivo CAR-T candidate, NT-001, which could significantly reduce treatment costs. The innovative approach exploits a unique lipid chemistry to avoid liver targeting, enhancing therapeutic delivery.